Literature DB >> 18367532

Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability.

Irina N Gavrilovskaya1, Elena E Gorbunova, Natalie A Mackow, Erich R Mackow.   

Abstract

Hantaviruses infect human endothelial cells and cause two vascular permeability-based diseases: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Hantavirus infection alone does not permeabilize endothelial cell monolayers. However, pathogenic hantaviruses inhibit the function of alphav beta3 integrins on endothelial cells, and hemorrhagic disease and vascular permeability deficits are consequences of dysfunctional beta3 integrins that normally regulate permeabilizing vascular endothelial growth factor (VEGF) responses. Here we show that pathogenic Hantaan, Andes, and New York-1 hantaviruses dramatically enhance the permeability of endothelial cells in response to VEGF, while the nonpathogenic hantaviruses Prospect Hill and Tula have no effect on endothelial cell permeability. Pathogenic hantaviruses directed endothelial cell permeability 2 to 3 days postinfection, coincident with pathogenic hantavirus inhibition of alphav beta3 integrin functions, and hantavirus-directed permeability was inhibited by antibodies to VEGF receptor 2 (VEGFR2). These studies demonstrate that pathogenic hantaviruses, similar to alphav beta3 integrin-deficient cells, specifically enhance VEGF-directed permeabilizing responses. Using the hantavirus permeability assay we further demonstrate that the endothelial-cell-specific growth factor angiopoietin 1 (Ang-1) and the platelet-derived lipid mediator sphingosine 1-phosphate (S1P) inhibit hantavirus directed endothelial cell permeability at physiologic concentrations. These results demonstrate the utility of a hantavirus permeability assay and rationalize the testing of Ang-1, S1P, and antibodies to VEGFR2 as potential hantavirus therapeutics. The central importance of beta3 integrins and VEGF responses in vascular leak and hemorrhagic disease further suggest that altering beta3 or VEGF responses may be a common feature of additional viral hemorrhagic diseases. As a result, our findings provide a potential mechanism for vascular leakage after infection by pathogenic hantaviruses and the means to inhibit hantavirus-directed endothelial cell permeability that may be applicable to additional vascular leak syndromes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367532      PMCID: PMC2395149          DOI: 10.1128/JVI.02397-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  92 in total

1.  Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor.

Authors:  Simon C Satchell; Steve J Harper; John E Tooke; Dontscho Kerjaschki; Moin A Saleem; Peter W Mathieson
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

Review 2.  Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?

Authors:  A R L Medford; A B Millar
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

3.  Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability.

Authors:  Patrice M Becker; Johannes Waltenberger; Robin Yachechko; Tamara Mirzapoiazova; James S K Sham; Chun Geun Lee; Jack A Elias; Alexander D Verin
Journal:  Circ Res       Date:  2005-05-26       Impact factor: 17.367

4.  Angiopoietin-1 opposes VEGF-induced increase in endothelial permeability by inhibiting TRPC1-dependent Ca2 influx.

Authors:  David Jho; Dolly Mehta; Gias Ahmmed; Xiao-Pei Gao; Chinnaswamy Tiruppathi; Michael Broman; Asrar B Malik
Journal:  Circ Res       Date:  2005-05-26       Impact factor: 17.367

5.  Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules.

Authors:  Fabienne Baffert; Tom Le; Gavin Thurston; Donald M McDonald
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-08-26       Impact factor: 4.733

Review 6.  Hantaviruses: a global disease problem.

Authors:  C Schmaljohn; B Hjelle
Journal:  Emerg Infect Dis       Date:  1997 Apr-Jun       Impact factor: 6.883

7.  Mechanisms of sphingosine and sphingosine 1-phosphate generation in human platelets.

Authors:  Motohiro Tani; Takamitsu Sano; Makoto Ito; Yasuyuki Igarashi
Journal:  J Lipid Res       Date:  2005-08-01       Impact factor: 5.922

8.  Evidence of a role for TRPC channels in VEGF-mediated increased vascular permeability in vivo.

Authors:  T M Pocock; R R Foster; D O Bates
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-10-09       Impact factor: 4.733

9.  VEGF induces hyperpermeability by a direct action on endothelial cells.

Authors:  S Hippenstiel; M Krüll; A Ikemann; W Risau; M Clauss; N Suttorp
Journal:  Am J Physiol       Date:  1998-05

10.  beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure.

Authors:  I N Gavrilovskaya; M Shepley; R Shaw; M H Ginsberg; E R Mackow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

View more
  81 in total

1.  Sangassou virus, the first hantavirus isolate from Africa, displays genetic and functional properties distinct from those of other murinae-associated hantaviruses.

Authors:  Boris Klempa; Peter T Witkowski; Elena Popugaeva; Brita Auste; Lamine Koivogui; Elisabeth Fichet-Calvet; Thomas Strecker; Jan Ter Meulen; Detlev H Krüger
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 2.  Uncovering the mysteries of hantavirus infections.

Authors:  Antti Vaheri; Tomas Strandin; Jussi Hepojoki; Tarja Sironen; Heikki Henttonen; Satu Mäkelä; Jukka Mustonen
Journal:  Nat Rev Microbiol       Date:  2013-08       Impact factor: 60.633

3.  Role of vascular and lymphatic endothelial cells in hantavirus pulmonary syndrome suggests targeted therapeutic approaches.

Authors:  Erich R Mackow; Elena E Gorbunova; Nadine A Dalrymple; Irina N Gavrilovskaya
Journal:  Lymphat Res Biol       Date:  2013-09-11       Impact factor: 2.589

Review 4.  Virus interactions with endothelial cell receptors: implications for viral pathogenesis.

Authors:  Nadine A Dalrymple; Erich R Mackow
Journal:  Curr Opin Virol       Date:  2014-07-24       Impact factor: 7.090

Review 5.  The Angiopoietin-Tie2 Signaling Axis in Systemic Inflammation.

Authors:  Samir M Parikh
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

6.  Sequential delivery of vascular endothelial growth factor and sphingosine 1-phosphate for angiogenesis.

Authors:  Jillian E Tengood; Kyle M Kovach; Patrick E Vescovi; Alan J Russell; Steven R Little
Journal:  Biomaterials       Date:  2010-07-31       Impact factor: 12.479

Review 7.  Lysophosphatidic Acid and Sphingosine-1-Phosphate: A Concise Review of Biological Function and Applications for Tissue Engineering.

Authors:  Bernard Y K Binder; Priscilla A Williams; Eduardo A Silva; J Kent Leach
Journal:  Tissue Eng Part B Rev       Date:  2015-07-14       Impact factor: 6.389

8.  Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin.

Authors:  Li-Wu Qian; Whitney Greene; Fengchun Ye; Shou-Jiang Gao
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  The detection of vascular endothelial growth factor in serum of patients with hemorrhagic fever with renal syndrome.

Authors:  Man Li; Yuqiang Ji; Yanying Dong; Yan Zhou; Huixun Ren; Ming Xie
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

10.  Profile of time-dependent VEGF upregulation in human pulmonary endothelial cells, HPMEC-ST1.6R infected with DENV-1, -2, -3, and -4 viruses.

Authors:  Azliyati Azizan; Kelly Fitzpatrick; Aimee Signorovitz; Richard Tanner; Heidi Hernandez; Lillian Stark; Mark Sweat
Journal:  Virol J       Date:  2009-05-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.